February 26, 2013 Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board
February 22, 2013 Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
December 20, 2012 Synthetic Biologics and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping Cough (Pertussis)
December 3, 2012 Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
November 30, 2012 Synthetic Biologics to Present at the Fifth Annual LD MICRO Conference in Los Angeles
November 12, 2012 Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
September 18, 2012 Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
